Key Insights

Highlights

Treatment Research

9 treatments under study, led by Paclitaxel

Research Leaders

5 sponsors active, led by LanZhou University

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

50.0%

2 terminated out of 4 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

4Total
Phase 2 (1)
Phase 3 (1)
Phase 4 (2)

Trial Status

Terminated2
Unknown2

Clinical Trials (4)

Showing 4 of 4 trials
NCT04325698Phase 3TerminatedPrimary

A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC

NCT03778853Phase 4UnknownPrimary

Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006)

NCT03768037Phase 4UnknownPrimary

Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC

NCT00369070Phase 2TerminatedPrimary

A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

Showing all 4 trials

Research Network

Common Treatments

  • Paclitaxel2
  • Carboplatin2
  • Anlotinib Hydrochloride1
  • Motesanib Diphosphate1
  • Bevacizumab1

Active Sponsors

  • LanZhou University1
  • Pfizer1
  • Guangdong Association of Clinical Trials1
  • General Hospital of Ningxia Medical University1
  • Amgen1

Top Investigators

Activity Timeline